SCOPUS 정보 검색 플랫폼

Acta Clinica Belgica

Volumn 51, Issue 4, 1996, Pages 254-260

Cytochrome P450: Genetic polymorphism and drug interactions

(2) Belpaire, F M a Bogaert, M G a

a GHENT UNIVERSITY (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRENOLOL; AMITRIPTYLINE; BUFURALOL; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CODEINE; CYTOCHROME P450; DESIPRAMINE; DIAZEPAM; ENCAINIDE; ERYTHROMYCIN; FLECAINIDE; HALOPERIDOL; IMIPRAMINE; ITRACONAZOLE; LIDOCAINE; METOPROLOL; NORTRIPTYLINE; PAROXETINE; PROPAFENONE; PROPRANOLOL; QUINIDINE; RISPERIDONE; SPARTEINE; TIMOLOL; UNINDEXED DRUG;

BIOTRANSFORMATION; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; LIVER METABOLISM; REVIEW;

EID: 0029764529 PISSN: 00015512 EISSN: None Source Type: Journal
DOI: 10.1080/22953337.1996.11718518 Document Type: Review

Times cited : (28)

References (14)

1
- 0024355863
- Genetic polymorphism of drug metabolism
- Dumont E, Belpaire F. Genetic polymorphism of drug metabolism. Acta Clin Belg. 1989; 44: 157-60.
- (1989) Acta Clin Belg , vol.44 , pp. 157-160
- Dumont, E.¹ Belpaire, F.²

2
- 0029028932
- Geographical/Interracial differences in polymorphic drug oxidation. Current status of knowledge of cytochromes P450 (CYP) 2D6 and 2C19
- Bertilsson L. Geographical/Interracial differences in polymorphic drug oxidation. Current status of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokin. 1995; 29: 192-209.
- (1995) Clin Pharmacokin , vol.29 , pp. 192-209
- Bertilsson, L.¹

3
- 0025269106
- Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics
- Brosen K. Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics. Clin Pharmacokin. 1990; 18: 220-39.
- (1990) Clin Pharmacokin , vol.18 , pp. 220-239
- Brosen, K.¹

4
- 0027983085
- Pharmacogenetic phenotyping and genotyping. Present status and future potential
- Gonzalez FJ, Idle J. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokin. 1994; 26: 59-70.
- (1994) Clin Pharmacokin , vol.26 , pp. 59-70
- Gonzalez, F.J.¹ Idle, J.²

5
- 0028204887
- The molecular basis of genetic polymorphisms of drug metabolism
- Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol. 1994; 46(suppl): 409-15.
- (1994) J Pharm Pharmacol , vol.46 , Issue.SUPPL. , pp. 409-415
- Meyer, U.A.¹

6
- 0026681168
- P450 enzymes: Inhibition mechanisms, genetic regulation and effects of liver disease
- Murray M. P450 enzymes: Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokin. 1992; 23:132-46.
- (1992) Clin Pharmacokin , vol.23 , pp. 132-146
- Murray, M.¹

7
- 0028289040
- Clinical implications of genetic polymorphism in drug metabolism
- Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol. 1994; 46(suppl): 417-24.
- (1994) J Pharm Pharmacol , vol.46 , Issue.SUPPL. , pp. 417-424
- Tucker, G.T.¹

8
- 0027446505
- The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature
- Nelson D, Kamataki T, Waxman D et al. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993; 12: 1-51.
- (1993) DNA Cell Biol , vol.12 , pp. 1-51
- Nelson, D.¹ Kamataki, T.² Waxman, D.³

9
- 0028088621
- Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: In vitro and in vivo findings and their implications for patient care
- Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull. 1994; 30: 251-9.
- (1994) Psychopharmacol Bull , vol.30 , pp. 251-259
- Preskorn, S.H.¹ Magnus, R.D.²

10
- 0028298286
- Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences
- Kivistö KT, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokin. 1994, 27:1-5.
- (1994) Clin Pharmacokin , vol.27 , pp. 1-5
- Kivistö, K.T.¹ Neuvonen, P.J.² Klotz, U.³

11
- 0029089702
- Ketoconazole to reduce the need for cyclosporine after cardiac transplantation
- Keogh A, Spratt P, McCosker MB, MacDonald P, Mundy BS, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med. 1995; 333: 628-32.
- (1995) N Engl J Med , vol.333 , pp. 628-632
- Keogh, A.¹ Spratt, P.² McCosker, M.B.³ MacDonald, P.⁴ Mundy, B.S.⁵ Kaan, A.⁶

12
- 0028153858
- Grapefruit juice and drugs. How significant is the interaction?
- Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs. How significant is the interaction? Clin Pharmacokin. 1994; 26:91-8.
- (1994) Clin Pharmacokin , vol.26 , pp. 91-98
- Bailey, D.G.¹ Arnold, J.M.O.² Spence, J.D.³

13
- 0025055648
- Enzyme induction in the cytochrome P-450 system
- Okey AB. Enzyme induction in the cytochrome P-450 system. Pharm Ther. 1990; 45: 241-98.
- (1990) Pharm Ther , vol.45 , pp. 241-298
- Okey, A.B.¹

14
- 0027328087
- In vitro approaches can predict human drug metabolism
- Birkett DJ, Mackenzie Pl, Veronese ME, Miners JO. In vitro approaches can predict human drug metabolism. TIPS. 1993; 14: 292-4.
- (1993) TIPS , vol.14 , pp. 292-294
- Birkett, D.J.¹ Mackenzie, Pl.² Veronese, M.E.³ Miners, J.O.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.